AndroGel Transfer to Women and Children: Alternatives Without This Side Effect

Why AndroGel Transfers Testosterone to Others

Testosterone topical gels work by delivering hormone through the stratum corneum into the bloodstream over several hours. The gel dries on the skin surface, but a pharmacokinetically active residue remains. That residue is the problem.

When another person touches the treated skin or contacts objects (clothing, towels, bedsheets) that touched the application site, they absorb testosterone transdermally. A 2012 pharmacokinetic study published in the Journal of Clinical Endocrinology & Metabolism found that vigorous skin-to-skin contact two hours after AndroGel 1.62% application transferred enough testosterone to raise serum levels in female subjects by 5- to 10-fold above baseline [1]. Even a T-shirt worn over the application site reduced, but did not eliminate, transfer [1].

The mechanism is straightforward. Testosterone gel leaves a depot of hormone in the outer skin layers. This depot can persist for 4 to 6 hours or longer after application. Contact during that window results in passive absorption by the second person. The amount transferred depends on three factors: time since application, surface area of contact, and whether the site was covered or washed.

Children are disproportionately vulnerable because of their lower body weight and developing endocrine systems. Doses that produce minimal systemic effect in a 200-pound adult male can cause clinically significant virilization in a 30-pound child. The FDA's prescribing information for AndroGel 1.62% documents cases of secondary exposure leading to premature pubic hair, phallic enlargement, advanced bone age, and aggressive behavior in children as young as 9 months [2].

The FDA Black Box Warning and FAERS Reports

The risk is not theoretical. In May 2009, the FDA mandated a boxed warning on all testosterone gel products after reviewing adverse event data [3]. This is the most serious warning category the agency issues.

Between 2000 and 2009, the FDA received reports of virilization in children who had contact with adults using testosterone gel. Reported effects included enlargement of the genitalia, early development of pubic hair, increased erections in boys, and advanced bone age. Some of these changes were not fully reversible after exposure stopped [3].

Dr. Mahyar Etminan, a pharmacoepidemiologist at the University of British Columbia, summarized the concern in a 2009 CMAJ commentary: "The clinical significance of inadvertent testosterone transfer is not trivial. In prepubertal children, even brief exposure can accelerate epiphyseal closure and compromise final adult height" [4].

A 2019 analysis of FDA Adverse Event Reporting System (FAERS) data identified testosterone topical products as one of the top five drug classes associated with pediatric accidental exposure reports [5]. The actual incidence is likely higher than FAERS captures, since passive surveillance systems typically capture only 1% to 10% of true adverse events.

How to Manage Transfer Risk If You Use Topical Testosterone

For men who choose to continue topical testosterone, the Endocrine Society's 2018 clinical practice guideline recommends strict adherence to the following precautions [6]:

Wash hands immediately after applying the gel. Soap and water remove residual testosterone from palms and fingers, the most common vectors for household transfer.

Cover the application site with clothing once the gel has dried (typically 5 to 10 minutes). A cotton T-shirt provides a physical barrier, though it does absorb some of the hormone into the fabric.

Wait at least 2 hours before allowing any skin-to-skin contact with a partner, child, or pet. If contact must happen sooner, wash the application site thoroughly with soap and water first.

Use the abdomen or inner thigh as the application site when possible. These areas are easier to keep covered and less likely to contact others during normal daily activities than shoulders or upper arms.

Avoid sharing towels, clothing, or bedding that has contacted the application site before laundering. Testosterone residue binds to fabric and can transfer during subsequent contact.

A 2006 study in Clinical Therapeutics evaluated whether a T-shirt barrier was sufficient to prevent transfer of testosterone gel (1% formulation). Wearing a shirt over the application site reduced testosterone transfer to a female partner by 92% when contact occurred 1 to 2 hours post-application [7]. Washing the site before contact reduced transfer by over 99% [7]. These measures are effective but require daily vigilance and consistent compliance.

The practical challenge is real. Households with young children involve constant physical contact. A father lifting a toddler, a child climbing into bed, or a partner resting against a shoulder are all routine events that can result in exposure if a single step is missed.

Injectable Testosterone: Zero Transfer Risk

Testosterone cypionate and testosterone enanthate, the two most widely prescribed injectable forms of TRT in the United States, completely eliminate transfer risk. The hormone is deposited directly into muscle or subcutaneous tissue and never contacts the skin surface.

Testosterone cypionate (Depo-Testosterone) is typically administered at 100 to 200 mg intramuscularly every 1 to 2 weeks, or 50 to 100 mg subcutaneously every week. A 2017 Journal of the Endocrine Society study showed that subcutaneous injection of testosterone cypionate 75 mg weekly produced more stable serum testosterone levels than biweekly intramuscular dosing, with fewer peak-trough fluctuations [8].

Testosterone enanthate follows a similar dosing schedule (100 to 200 mg intramuscularly every 1 to 2 weeks). Both esters are bioequivalent when dosed appropriately. The Endocrine Society 2018 guideline lists injectable testosterone as a first-line option alongside topical formulations, noting that injections "avoid the risk of interpersonal transfer" [6].

Cost is another advantage. Generic testosterone cypionate 200 mg/mL (10 mL vial) costs $30 to $80 at most pharmacies, compared to $200 to $600 per month for branded AndroGel without insurance. For men whose insurance does not cover brand-name gels, switching to injections saves money while eliminating the safety concern.

Self-injection at home is standard practice. Most patients learn the technique in one clinic visit. Subcutaneous injection into abdominal fat uses a small 25- to 27-gauge needle and is well-tolerated.

The trade-off is pharmacokinetics. Injections produce a peak in testosterone 24 to 48 hours after administration, followed by a gradual decline. Some men report mood or energy fluctuations tied to this cycle. Weekly subcutaneous dosing minimizes this pattern and is increasingly preferred by clinicians.

Testosterone Pellets: Implanted and Inaccessible

Testopel (testosterone pellets) consists of 75 mg crystalline testosterone pellets implanted subcutaneously in the hip or buttock. A typical dose is 6 to 12 pellets (450 to 900 mg), inserted through a small trocar incision every 3 to 6 months.

Because the testosterone is physically embedded under the skin, there is no possibility of surface transfer. A 2013 retrospective cohort study in Sexual Medicine Reviews found that pellet therapy maintained eugonadal testosterone levels (400 to 700 ng/dL) for a mean duration of 4.2 months per insertion, with 94% patient satisfaction at 12-month follow-up [9].

Pellets are especially suitable for men in households with young children or pregnant partners. Once the insertion site heals (5 to 7 days), no daily precautions or routine are required.

Downsides include the minor in-office procedure, rare pellet extrusion (reported in 2% to 12% of insertions depending on the series), and inability to adjust the dose quickly once pellets are placed. If side effects occur, the testosterone continues releasing until the pellets are fully absorbed.

Nasal Testosterone: Natesto

Natesto (testosterone nasal gel, 5.5 mg per pump) is applied inside each nostril three times daily. The gel is absorbed through the nasal mucosa and never contacts external skin.

An open-label phase 3 trial enrolled 306 hypogonadal men and found that 90% achieved a serum testosterone concentration in the normal range (300 to 1 to 050 ng/dL) at 90 days [10]. The FDA approved Natesto in 2014, and the prescribing information confirms that secondary transfer studies found no meaningful testosterone exposure in female partners after nasal application [11].

A distinctive advantage of Natesto is its short half-life. Each dose produces a testosterone pulse that returns to baseline within 4 to 6 hours. This pulsatile pattern more closely mimics the body's natural diurnal testosterone rhythm than gels or injections. Preliminary data from a 2019 study in The Journal of Urology suggested that Natesto may be less suppressive of spermatogenesis than other TRT formulations, making it a consideration for men who wish to preserve fertility [12].

The three-times-daily dosing schedule is the main drawback. Compliance data from real-world use shows that adherence drops when medications require more than twice-daily dosing. Nasal irritation, rhinorrhea, and epistaxis occurred in 3% to 5% of subjects in the phase 3 trial [10].

Testosterone Undecanoate Injection: Extended-Interval Dosing

Aveed (testosterone undecanoate, 750 mg/3 mL) is an intramuscular injection given every 10 weeks after a loading phase. It eliminates transfer risk and reduces injection frequency to roughly five times per year.

A multicenter study published in The Journal of Clinical Endocrinology & Metabolism demonstrated that Aveed maintained average serum testosterone at 496 ng/dL over 84 weeks, with 94% of trough measurements in the eugonadal range [13].

Aveed must be administered in a healthcare setting and requires a 30-minute post-injection observation period due to a rare risk of pulmonary oil microembolism (POME). This reaction occurred in fewer than 1% of injections in post-marketing surveillance [13]. The in-office requirement and REMS (Risk Evaluation and Mitigation Strategy) program add inconvenience but provide an additional safety layer.

For men who want a set-it-and-forget-it approach without transfer risk, Aveed offers the longest interval between doses of any FDA-approved injectable TRT.

Comparing Alternatives: A Decision Framework

The Endocrine Society 2018 guideline recommends choosing a TRT formulation based on "patient preference, pharmacokinetics, treatment burden, and cost" [6]. When a household includes women or children, the guideline specifically advises considering non-topical options [6].

Dr. Shalender Bhasin, Professor of Medicine at Harvard Medical School and lead author of the 2018 guideline, stated: "For men living with young children or pregnant partners, injectable or implantable testosterone formulations offer equivalent efficacy without the compliance burden of daily skin-contact precautions" [6].

Here is how the main alternatives compare on key dimensions:

• Testosterone cypionate/enanthate injection: Zero transfer risk. Weekly to biweekly dosing. Lowest cost ($30 to $80/month). Self-administered at home.
• Testosterone undecanoate (Aveed): Zero transfer risk. Every-10-week dosing. Requires in-office administration. Higher cost ($1,000 to $1,500 per injection before insurance).
• Testosterone pellets (Testopel): Zero transfer risk. Every 3 to 6 months. Requires minor procedure. Moderate cost ($500 to $900 per insertion).
• Nasal testosterone (Natesto): Negligible transfer risk. Three-times-daily dosing. May preserve fertility. Moderate cost ($200 to $500/month).
• Topical gel with precautions: Transfer risk reduced but not eliminated. Daily application with strict hygiene protocol required.

When to Talk to Your Doctor About Switching

Any man using topical testosterone who lives with children under 18, a pregnant or potentially pregnant partner, or a female partner experiencing unexplained virilization symptoms should discuss formulation alternatives at his next visit. Signs of secondary exposure in a household contact include new acne, increased body hair, voice deepening, clitoral enlargement, or precocious puberty signs in a child (pubic hair, body odor, growth spurt before age 8 in girls or age 9 in boys).

The switch itself is clinically straightforward. A man on AndroGel 1.62% (40.5 mg daily) producing a mid-range testosterone level might transition to testosterone cypionate 80 to 100 mg subcutaneously weekly with a follow-up lab in 6 to 8 weeks. No washout period is needed. Serum testosterone typically stabilizes within 2 to 3 injection cycles [6].

Men who are stable and satisfied on topical testosterone and who live alone or with adult partners only may not need to switch, provided they follow recommended precautions consistently. The choice is about household context and risk tolerance, not inherent superiority of one formulation over another. Every FDA-approved TRT option achieves equivalent testosterone restoration when dosed correctly [6].